The FDA is warning that parents should avoid using neck floats for infants with special needs or developmental delays.
. Some of these products are being marketed for infants as young as 2 weeks old, as well as for premature babies. But the FDA said the safety and effectiveness of the products for these children have not been proved.
The floats “have not been evaluated by the FDA and we are not aware of any demonstrated benefit with the use of neck floats for water therapy interventions,” the agency said in the June 28 statement. While injuries and deaths from neck floats are rare, the FDA said families and caregivers should be aware that these incidents can and do occur., the FDA Safety Information and Adverse Event Reporting Program. Health care personnel employed by the FDA are required to file new reports with the FDA.FDA: “Do Not Use Baby Neck Floats Due to the Risk of Death or Injury: FDA Safety Communication.”
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Warns Against Baby Neck Floats After A Reported DeathThe organization urged caregivers to stop using inflatable neck floats, especially with babies who have developmental delays or special needs.
Read more »
FDA temporarily suspends order banning Juul cigarettesThe Food and Drug Administration has issued a stay of its recent order for vaping company Juul to pull its electronic cigarettes from the market. The FDA says the stay is temporary while it conducts further review.
Read more »
'Unique' Issues Cause FDA To Temporarily Suspend Ban On Juul CigarettesThe FDA issued the initial order banning Juul sales on June 23. A day later, a federal appeals court temporarily blocked the government ban.
Read more »
FDA temporarily suspends order banning Juul cigarettesThe Food and Drug Administration said on Twitter that the stay temporarily suspends the marketing denial order while it conducts further review, but does not rescind it.
Read more »
FDA decision on Eisai, Biogen Alzheimer's drug due in JanuaryThe U.S. Food and Drug Administration will expedite its review of Eisai Co Ltd's and Biogen Inc's experimental Alzheimer's drug lecanemab, with a decision due by Jan 6, 2023, the companies said on Tuesday.
Read more »
Juul Can Keep Selling Its Products in U.S. While It Appeals Ban, FDA SaysThe FDA says it will allow Juul to stay on the U.S. market while the e-cigarette maker appeals the agency’s ban
Read more »